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Neurotensin and xenin possess antidiabetic potential, mediated in part through augmentation 2 
of incretin hormone, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 3 
polypeptide (GIP), action. In this study, fragment peptides of neurotensin and xenin, acetyl-4 
neurotensin (8-13) and xenin-8-Gln, were fused together to create Ac-NT/XN-8-Gln. 5 
Following assessment of enzymatic stability, effects of Ac-NT/XN-8-Gln on in vitro beta-cell 6 
function were studied. Sub-chronic antidiabetic efficacy of Ac-NT/XN-8-Gln alone, and in 7 
combination with the clinically approved GLP-1 receptor agonist exendin-4, was assessed in 8 
high fat fed (HFF) mice. Ac-NT/XN-8-Gln was highly resistant to plasma enzyme degradation 9 
and induced dose-dependent insulin-releasing actions (p<0.05 to p<0.01) in BRIN-BD11 beta-10 
cells and isolated mouse islets. Ac-NT/XN-8-Gln augmented (p<0.001) the insulinotropic 11 
actions of GIP, while possessing independent beta-cell proliferative (p<0.001) and anti-12 
apoptotic (p<0.01) actions. Twice daily treatment of HFF mice with Ac-NT/XN-8-Gln for 32 13 
days improved glycaemic control and circulating insulin, with benefits significantly enhanced 14 
by combined exendin-4 treatment. This was reflected by reduced body fat mass (p<0.001), 15 
improved circulating lipid profile (p<0.01) and reduced HbA1c concentrations (p<0.01) in the 16 
combined treatment group. Following an oral glucose challenge, glucose levels were markedly 17 
decreased (p<0.05) only in combination treatment group and superior to exendin-4 alone, with 18 
similar observations made in response to glucose plus GIP injection. The combined treatment 19 
group also presented with improved insulin sensitivity, decreased pancreatic insulin content as 20 
well as increased islet and beta-cell areas. These data reveal that Ac-NT/XN-8-Gln is a 21 
biologically active neurotensin/xenin fusion peptide that displays prominent antidiabetic 22 
efficacy when administered together with exendin-4. 23 
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Neurotensin and xenin are regulatory peptides that share amino acid sequence homology, 2 
activate similar receptors and possess some notable parallels in their bioactivity profiles (1,2). 3 
Both hormones stimulate appetite suppression (2-4) as well as modulate insulin secretion and 4 
glucose homeostasis (3,5). Positive effects of neurotensin and xenin have been observed also 5 
on pancreatic beta-cell growth and survival (4,6), together with prominent effects on metabolic 6 
regulation. In this regard, there is good evidence that neurotensin is co-expressed and co-7 
released with the incretin hormone glucagon-like peptide-1 (GLP-1) from intestinal L-cells (4), 8 
whilst xenin is similarly secreted alongside glucose-dependent insulinotropic polypeptide 9 
(GIP) from enteroendocrine K-cells (2). However, it should also be noted that neurotensin is 10 
also synthesised and secreted by enteroendocrine N-cells (7), suggesting that secretion of GLP-11 
1 and NT are not fully paralleled in vivo. Nonetheless, neurotensin has recently been shown to 12 
augment the biological actions of GLP-1 (8), while xenin is well known to potentiate GIP 13 
mediated bioactivity (9-11). Thus, together neurotensin and xenin have the capacity to 14 
significantly enhance the biological actions of the incretin hormones. This is of particular 15 
interest in terms of the treatment of type 2 diabetes, given that a number of clinically approved 16 
antidiabetic therapeutics directly modulate the incretin system (12), with other agents believed 17 
to exert some of their benefits through this pathway (13,14).  18 
Interestingly, the C-terminal portions of both neurotensin and xenin have been shown 19 
to retain similar bioactivity as their respective parent peptides (15,16). This would suggest that 20 
shorter neurotensin and xenin peptides which are easier to synthesise and formulate, may have 21 
therapeutic promise for diabetes. One potential hindrance to the use of such truncated 22 
neurotensin or xenin peptides relates to their relatively brief biological half-lives (16,17). 23 
However, enzymatic stability and subsequent prolongation of bioactivity, can be imparted 24 
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such, acetyl-neurotensin(8-13) and xenin-8-Gln represent fully characterised, enzymatic 1 
resistant, bioactive neurotensin and xenin peptide analogues (19,20). To increase therapeutic 2 
applicability of gut hormone derived peptides, generation of hybrid unimolecular peptides has 3 
been employed of late, through merging of the key bioactive amino acid sequences of the parent 4 
peptides (21-23). Based on this knowledge, we have constructed a novel neurotensin/xenin 5 
hybrid peptide, namely Ac-NT/XN-8-Gln, by fusing together the amino acid sequences of 6 
acetyl-neurotensin(8-13) and xenin-8-Gln. The xenin component of the fusion peptide was 7 
positioned at the C-terminus, as this has been employed with good success for other xenin 8 
hybrid peptides (24-26).   9 
In the current study, we initially examined plasma stability of Ac-NT/XN-8-Gln 10 
followed by assessment of in vitro insulinotropic actions alone, and in combination with GIP 11 
or GLP-1. In addition, the impact of Ac-NT/XN-8-Gln on beta-cell proliferation and protection 12 
against apoptosis was also investigated in BRIN-BD11 beta-cells. Following confirmation of 13 
intact bioactivity of Ac-NT/XN-8-Gln, beneficial metabolic effects of twice daily 14 
administration alone, or in combination with exendin-4, were evaluated in high fat fed (HFF) 15 
mice.  16 
 17 
Materials and Methods 18 
Peptides 19 
All peptides (Table 1) were purchased from Syn Peptide (Shanghai, China) at greater than 95% 20 
purity. In-house confirmation of peptide purity and molecular weight was carried out by RP-21 
HPLC and MALDI-TOF MS, as previously described (27). 22 
 23 
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The in vitro insulin secretory activity of test peptides was examined in BRIN-BD11 cells, 1 
cultured and maintained as previously described (28). For experimentation, BRIN-BD11 cells 2 
were seeded in 24-well plates at a cell density of 150,000 cells/well, and allowed to attach 3 
overnight at 37oC. Following pre-incubation with Krebs–Ringer bicarbonate buffer (KRBB) 4 
(pH 7.4) supplemented with 0.5% (w/v) BSA and 1.1 mM glucose (40 min; 37 °C), cells were 5 
then incubated with test peptides alone (10-6 – 10-12 M), or in combination with either GIP or 6 
GLP-1 (10-7 M), at 5.6 or 16.7 mM glucose, as appropriate for 20 minutes. Relatively high 7 
concentrations of GIP and GLP-1 were employed for in vitro studies and these hormones have 8 
been shown to be synthesised and secreted locally within islets (29), with our previous studies 9 
confirming that augmentation of the insulinotropic actions of 10-7 M GIP or GLP-1 is 10 
achievable (30,31). Aliquots of assay buffer (200 μl) were collected and stored at -20 °C prior 11 
to assessment of insulin concentrations by an in-house radioimmunoassay (32). To confirm 12 
insulin secretory activity of Ac-NT/XN-8-Gln, pancreatic islets were isolated from lean 13 
C57BL/6 mice by collagenase digestion, as described previously (33) and insulin secretion 14 
determined as outlined above (16.7 mM glucose), but over a 60 min test incubation period. 15 
 16 
Effects of peptides on in vitro beta-cell proliferation and protection against apoptosis  17 
BRIN-BD11 beta-cells were used to investigate effects of test peptides (10−8 and 10−6 M) on 18 
beta-cell proliferation and protection against apoptosis. GLP-1 was employed as a positive 19 
control for all studies. Ki-67 immunostaining was used to assess effects on proliferation. 20 
Briefly, cells were seeded onto coverslips (40,000 cells per coverslip) and cultured overnight 21 
(18 h;37 °C), in the presence of test peptides (10−8 and 10−6 M). Cells were then washed with 22 
PBS, and fixed using 4% paraformaldehyde. Following antigen retrieval with citrate buffer 23 
(90°C for 20 min), tissues were blocked using 1.1% BSA for 30 min. Cells were then incubated 24 
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secondary antibody (1:400, Invitrogen, A-11008). Coverslips were washed with PBS, mounted 1 
on slides for viewing using a fluorescent microscope (Olympus System Microscope) and 2 
photographed by DP70 camera adapter system. Proliferation frequency was expressed as 3 
percentage of total cells analysed. For analysis of the ability of test peptides (10−8 and 10−6 M) 4 
to protect against apoptosis, cells were seeded as above, but apoptosis evoked through 5 
activation of caspase 3 and 7 activity by a luminogenic, tetrapeptide sequence DEVD Caspase-6 
Glo® 3/7 substrate. Caspase induced cleavage of the substrate was then assessed by an 7 
ApoLive-Glow™ Multiplex assay kit, according to the protocol provided by the manufacturer 8 
(Promega, Wisconsin, USA). 9 
 10 
Animals 11 
Studies were carried out using male NIH Swiss mice (12-14 weeks of age, Envigo Ltd, UK), 12 
housed individually in an air-conditioned room at 22 ± 2 °C with a 12 h light:12 h dark cycle. 13 
Prior to experiments, animals were maintained on a high-fat diet (45% fat, 35% carbohydrate 14 
and 20% protein, Special Diet Services, UK, with percent of total energy of 26.15 kJ/g) for 10 15 
weeks. This diet resulted in progressive body weight gain and hyperglycaemia compared to 16 
control mice. Lean control animals were maintained on a standard rodent chow diet (10% fat, 17 
30% protein and 60% carbohydrate, Trouw Nutrition, UK, with percent of total energy of 12.99 18 
kJ/g). All mice had ad libitum access to water and respective diets. Experiments were carried 19 
out in accordance with the UK Animal Scientific Procedures Act 1986 and approved by the 20 
University of Ulster Animal Welfare and Ethical Review Body (AWERB) under the UK Home 21 
Office project licence 2804. All animal studies were conducted in the Biomedical and 22 
Behavioural Research Unit (BBRU) at Ulster University, Coleraine. 23 
 24 
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Twice daily i.p. injections of saline vehicle (0.9% w/v NaCl), exendin-4, Ac-NT/XN-8-Gln or 1 
a combination of both peptides (each peptide at 25 nmol/kg bw) were administered at 09:30 h 2 
and 17:30 h for 32-days in HFF mice. Cumulative food intake, body weight, non-fasting 3 
glucose and insulin concentrations were monitored at regular intervals. HbA1c concentrations 4 
were measured on day 32. In addition, at the end of the treatment period, oral glucose tolerance 5 
(18 mmol/kg bw; p.o.), biological response to GIP (18 mmol/kg glucose in combination with 6 
native GIP (25 nmol/kg); i.p.) and insulin sensitivity (15 U/kg bw; i.p.) tests were performed. 7 
All test solutions were administered in a final volume of 5 ml/kg body weight.  8 
 9 
Terminal analyses 10 
All animals were euthanised via CO2 gas inhalation and cervical dislocation. Percentage body 11 
fat mass was measured at study termination by DEXA scanning (PIXImus Densitometer; Inside 12 
Outside Sales, Fitchburg, WI, USA). Pancreatic insulin content was measured following 13 
hormone extraction (1.5% HCl, 75% ethanol and 23.5% H2O), as described previously (34). 14 
For histological analyses, tissue was excised, immediately fixed using 4% paraformaldehyde 15 
and embedded in paraffin wax. Tissue sections were then deparaffinised, rehydrated and 16 
probed with primary antibodies, namely mouse anti-insulin antibody (1:500; Abcam, ab6995) 17 
and guinea-pig anti-glucagon antibody (PCA2/4, 1:400; raised in-house). Sections were 18 
incubated with secondary antibodies, Alexa Fluor 594 goat anti-mouse IgG (1:400) and Alexa 19 
Fluor 488 goat anti-guinea pig IgG (1:400). The slides were viewed under a FITC (488 nm) or 20 
TRITC filter (594 nm) using a fluorescent microscope (Olympus system microscope, model 21 
BX51) and photographed using a DP70 camera adapter system. Islet parameters were analysed 22 
using CellF image analysis software (Olympus Soft Imaging Solutions, GmbH).  23 
 24 
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Blood samples were collected from the tail vein of conscious mice into chilled fluoride/heparin 1 
glucose microcentrifuge tubes (Sarstedt, Numbrecht, Germany) at the time points indicated in 2 
the Figures. Blood glucose was measured directly using a handheld Ascensia Contour blood 3 
glucose meter (Bayer Healthcare, Newbury, Berkshire, U.K.). HbA1c concentrations in whole 4 
blood were measured using A1cNow® kits (PTS diagnostics, Indiana, USA). Total and LDL-5 
cholesterol, as well as blood triacylglycerol concentrations, were measured using a Hitachi 6 
Automated Analyser 912 (Boehringer Ingelheim, Mannheim, Germany). Plasma and 7 
pancreatic insulin were assayed by a modified dextran-coated charcoal radioimmunoassay, as 8 
described previously (32).  9 
 10 
Statistical analysis 11 
Statistical analysis was performed using GraphPad PRISM (Version 5). Results are expressed 12 
as means ± SEM and data compared using repeated measures ANOVA followed by the 13 
Student-Newman-Keuls post hoc test. Unpaired student t-test was used where appropriate. 14 
Area under curve (AUC) and area above curve (AAC) analyses were calculated using 15 
trapezoidal rule with baseline subtraction. Groups of data were significantly different if p<0.05. 16 
 17 
Results 18 
Plasma enzyme stability 19 
When incubated together with murine plasma, Ac-NT/XN-8-Gln remained 100% intact up to 20 
and including 4 h, and over 90% peptide intact over an extended 8 h incubation period (Table 21 
1). Native GLP-1 was employed as a positive control in this system, and was fully degraded 22 
by 4 h (data not shown). 23 
 24 
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The insulinotropic actions of Ac-NT/XN-8-Gln, and respective parent peptides, at 5.6 and 16.7 1 
mM glucose were investigated in BRIN-BD11 cells. At 5.6 mM glucose, xenin-8-Gln increased 2 
(p<0.05 – p<0.001) insulin secretion at concentrations of 10-8 M and above, whilst acetyl-3 
neurotensin(8-13) and Ac-NT/XN-8-Gln evoked a significant (p<0.05) increase of insulin 4 
secretion at 10-6 M (Figure 1A). Interestingly, at 16.7 mM glucose only xenin-8-Gln retained 5 
significant insulinotropic actions, whereas acetyl-neurotensin(8-13) inhibited (p<0.05) 6 
glucose-stimulated insulin secretion (Figure 1B). Xenin-8-Gln augmented (p<0.05 – p<0.01) 7 
GIP-induced insulin secretion but had no impact on GLP-1 evoked insulin release, with Ac-8 
NT/XN-8-Gln possessing a similar, but more prominent, bioactivity profile in the presence of 9 
GIP (Figure 1C,D). Interestingly, acetyl-neurotensin(8-13) had no effect on GIP-induced 10 
insulin release and appeared to inhibit (p<0.05) GLP-1 related insulin secretion (Figure 1C,D). 11 
Prominent (p<0.01) insulinotropic actions of Ac-NT/XN-8-Gln were then confirmed in 12 
isolated mouse islets at 16.7 mM glucose (Figure 1E).  13 
 14 
Effects of Ac-NT/XN-8-Gln on beta-cell proliferation and protection against apoptosis 15 
Similar to exendin-4, but with some reduced efficacy, acetyl-neurotensin(8-13) and Ac-16 
NT/XN-8-Gln significantly (p<0.001) augmented BRIN-BD11 beta-cell proliferation at 17 
concentrations of 10−8 and 10−6 M (Figure 2A). Interestingly, in the current setting xenin-8-Gln 18 
was devoid of benefits on beta-cell proliferation, with the actions of Ac-NT/XN-8-Gln being 19 
significantly (p<0.05 – p<0.01) superior to xenin-8-Gln (Figure 2A). In relation to protection 20 
against apoptosis, all test peptides protected against (p<0.01 - p<0.001) BRIN-BD11 beta-cell 21 
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Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in 1 
combination, on body weight, food intake, glucose, insulin and HbA1c concentrations in 2 
HFF mice 3 
Twice-daily administration of exendin-4 alone to HFF mice reduced (p<0.05 – p<0.01) 4 
cumulative energy intake from day 17 onwards when compared to HFF control mice, an effect 5 
that was not observed with any of the other treatment modalities (Figure 3A). Body weight was 6 
significantly decreased (p<0.05 – p<0.001) in mice receiving exendin-4 alone, or in 7 
combination with Ac-NT/XN-8-Gln (Figure 3B), but there was no obvious benefit of adding 8 
Ac-NT/XN-8-Gln to exendin-4 therapy in terms of overall body weight change (Figure 3B). 9 
Moreover, body fat mass was especially reduced (p<0.001) in HFF mice treated with Ac-10 
NT/XN-8-Gln in combination with exendin-4 (Figure 3C). Non-fasting blood glucose levels 11 
were declined to levels similar to that of lean controls in HFF mice treated with exendin-4 12 
alone, or in combination with Ac-NT/XN-8-Gln on day 4, and remained at normoglycaemic 13 
levels throughout in these groups of HFF mice (Figure 3D). In full agreement, HbA1c 14 
concentrations on day 32 were identical to lean controls in HFF mice treated with exendin-4 15 
alone, or in combination with Ac-NT/XN-8-Gln (Figure 3E). Similarly, circulating insulin was 16 
elevated (p<0.05 – p<0.001) only in HFF mice receiving exendin-4 alone, or in combination 17 
with Ac-NT/XN-8-Gln (Figure 3F). 18 
 19 
Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in 20 
combination, on glucose tolerance, metabolic response to GIP, insulin sensitivity and lipid 21 
status in HFF mice 22 
Following an oral glucose challenge, individual and 0-120 min AUC glucose levels were 23 
significantly decreased (p<0.05) only in mice treated with Ac-NT/XN-8-Gln in combination 24 
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control mice (Figure 4A,B). In this respect, combination treatment was more effective than 1 
either parent peptide alone. There was a tendency for glucose-induced insulin secretion to be 2 
augmented in all HFF treatment groups, but this failed to reach significance (Figure 4C,D). 3 
Strikingly similar observations were made in response to glucose plus GIP injection, with only 4 
the combination treatment group evoking significant (p<0.05) metabolic benefits of GIP 5 
(Figure 4E-H), and superior to Ac-NT/XN-8-Gln or exendin-4 alone. These improvements in 6 
metabolism were associated with significantly improved (p<0.05) insulin sensitivity in the 7 
combined treatment group, that was not apparent with either individual peptide treatment 8 
(Figure 5A,B). In keeping with benefits of combined therapy, treatment of Ac-NT/XN-8-Gln 9 
in combination with exendin-4 reduced (p<0.05) circulating triacylglycerols (Figure 5C). In 10 
addition, both exendin-4 alone, and in combination with Ac-NT/XN-8-Gln, decreased (p<0.01) 11 
total-cholesterol concentrations (Figure 5D), with LDL-cholesterol also decreased (p<0.01) in 12 
these groups of mice when compared to treatment with Ac-NT/XN-8-Gln alone (Figure 5E). 13 
 14 
Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in 15 
combination, on pancreatic insulin content and islet histology in HFF mice 16 
Treatment with exendin-4 alone and in combination with Ac-NT/XN-8-Gln for 32 days 17 
decreased (p<0.001) pancreatic insulin content when compared to HFF control mice, with 18 
levels similar to that of lean controls (Figure 6A). HFF mice had significantly (p<0.001) 19 
increased islet area compared with lean controls (Figure 6B), that was associated with 20 
characteristic adaptive increases (p<0.001) in beta-cell area (Figure 6C). Treatment with 21 
exendin-4 alone, and even more so in combination with Ac-NT/XN-8-Gln, further increased 22 
(p<0.05 – p<0.01) islet and beta-cell areas (Figure 6B,C). Interestingly, although there was a 23 
tendency for alpha-cell area to be decreased by each treatment regimen, there were no 24 
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Discussion  2 
Original early work demonstrated direct additive benefits of combined activation of GIP and 3 
xenin signalling pathways on pancreatic beta-cell function and metabolism (10), which have 4 
been largely confirmed by others (24,35). More recently, additive, or potentially synergistic, 5 
positive effects of combined GLP-1 and neurotensin signalling have also been evidenced (8). 6 
Indeed, there is also suggestion that xenin can directly affect GLP-1 secretion and action 7 
(25,36), with neurotensin having a potentially comparable effect on GIP activity (37). Taken 8 
together, neurotensin and xenin have the combined ability to modulate and augment the incretin 9 
effect, with obvious therapeutic implications for diabetes. This is even more apparent, given  10 
that highly prominent preclinical benefits of incretin enhancer drugs have not been fully 11 
translated to the clinic. Thus, the present study was designed to incorporate the metabolic 12 
advantages of neurotensin and xenin within a single unimolecular peptide, namely Ac-NT/XN-13 
8-Gln, with subsequent characterisation of biological activity and assessment of ability to 14 
augment the antidiabetic efficacy of an established incretin mimetic drug.    15 
As expected, Ac-NT/XN-8-Gln was highly resistant to enzymatic breakdown, in 16 
keeping with enhanced stability of the parent peptides acetyl-neurotensin(8-13) and xenin-8-17 
Gln  (19,20). We were unable to perform in vivo pharmacokinetic analysis of Ac-NT/XN-8 as 18 
the specific assay required for such experiments is currently unavailable.  Encouragingly 19 
however, Ac-NT/XN-8-Gln displayed prominent in vitro and ex vivo insulin secretory actions, 20 
and unlike neurotensin related peptides (38), insulinotropic actions were evident under 21 
hyperglycaemic conditions. Thus, xenin peptides have been consistently shown to promote 22 
insulin secretion at both basal and elevated glucose levels (39,40), whereas neurotensin 23 
possesses reduced insulin secretory effectiveness at increased glucose concentrations (41). 24 
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as has been demonstrated previously with both native neurotensin and xenin (6,42). Positive 1 
effects on pancreatic beta-cell function and turnover are consistent with local synthesis and 2 
secretion of both hormones within the endocrine pancreas, and related essential physiological 3 
actions (2,4). Thus, immunohistochemical analyses confirm the presence of both neurotensin 4 
and xenin immunoreactivity locally within islets (6). Interestingly, in our experimental system, 5 
we were unable to recapitulate the potentiating effect of neurotensin on GLP-1 bioactivity (4,7), 6 
with acetyl-neurotensin(8-13) and Ac-NT/XN-8-Gln both appearing to perturb GLP-1 induced 7 
insulin secretion. However, in accord with previous observations (20), xenin-8-Gln clearly 8 
augmented GIP stimulated insulin secretion, with Ac-NT/XN-8-Gln fully replicating this 9 
beneficial effect, thus Ac-NT/XN-8-Gln may function more like xenin at the level of the 10 
pancreatic beta-cell. In this regard, the receptor activation profile of Ac-NT/XN-8-Gln requires 11 
further detailed investigation, especially since the exact receptor that xenin signals through has 12 
not been fully established to date (35). Thus, use of commercially available neurotensin 13 
receptor antagonists, or receptor knockout cell lines, may be useful to help uncover the 14 
receptors that are positively modulated by Ac-NT/XN-8-Gln. However, at the level of the 15 
pancreatic beta-cell, it is clear that Ac-NT/XN-8-Gln retains ability to activate similar cell 16 
signaling pathways as the parent peptides, and we assume that this is also true in other tissues 17 
that express neurotensin or xenin receptors (2).    18 
Following confirmation of enzymatic stability and preserved bioactivity of Ac-NT/XN-19 
8-Gln, a chronic 32-day investigation of Ac-NT/XN-8-Gln antidiabetic actions alone, and in 20 
combination with the clinically approved GLP-1 mimetic, exendin-4, was conducted in the 21 
HFF mice. An additional group receiving exendin-4 alone was included as control. Although 22 
neurotensin and xenin are known to exert appetite suppressive actions (4,20,43), similar to 23 
GLP-1 (44), only treatment with exendin-4 alone decreased energy intake in HFF mice in the 24 
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apparent, although to a lesser extent, with combined Ac-NT/XN-8-Gln injection. Indeed, 1 
exendin-4 induced benefits on circulating glucose levels were not improved by 2 
supplementation therapy with Ac-NT/XN-8-Gln. More interestingly however, the most 3 
prominent reduction of body fat content was noted in the combined treatment group, suggesting 4 
important benefits on lipid metabolism and body composition by co-activation of GLP-1, 5 
neurotensin and xenin signalling pathways in HFF mice. In agreement, whilst circulating lipid 6 
profile of HFF mice was improved by all treatment regimens, only combined therapy reduced 7 
triacylglycerol concentrations. In this regard, originally it was believed that xenin acts on 8 
adipose tissue to stimulate lipolysis (45), but more recent studies reveal direct lipogenic and 9 
adipocyte differentiation actions of xenin (46). In agreement, an elegant study has suggested 10 
that neurotensin can also promote lipid accumulation (47). However, activation of all three 11 
hormone signalling pathways appears to lead to reduced lipid deposition. In some agreement, 12 
interaction between xenin and GIP pathways within adipocytes has previously been noted to 13 
induce responses that contrast to effects of either hormone alone (46). 14 
Decreased adiposity would be expected to improve insulin sensitivity (48), and this was 15 
very much apparent in HFF mice treated with a combination of Ac-NT/XN-8-Gln and exendin-16 
4. Whilst GLP-1 is well recognised to improve insulin action (49), similar observations have 17 
also been made with xenin-based peptides (2). Moreover, neurotensin is believed to be an 18 
important driving factor behind the improvement of insulin sensitivity in obese patients after 19 
metabolic surgery (50). The same combined treatment group also displayed significantly 20 
improved glucose handling and glucose-lowering actions of GIP when compared to all other 21 
groups of HFF mice, despite no obvious augmentation of corresponding glucose- or GIP-22 
induced insulin secretion, again suggesting improvement of insulin action in peripheral tissues. 23 
Additive benefits of Ac-NT/XN-8-Gln and exendin-4 to improve glucose disposal could also 24 
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this would require further detailed investigation. However, pancreatic insulin stores were 1 
decreased in HFF mice treated with Ac-NT/XN-8-Gln in combination with exendin-4, 2 
implying reduced metabolic demand. Despite this, the characteristic expansion of pancreatic 3 
beta-cells by sustained high fat feeding in mice (52) was amplified by combined therapy, and 4 
likely linked to the increase of circulating insulin witnessed in these mice, although it should 5 
be noted that circulating insulin levels were also similarly increased in mice receiving exendin-6 
4 alone. Such observations are in harmony with GLP-1 mediated benefits on beta-cell mass 7 
(53), as well as in direct agreement with our in vitro observations with Ac-NT/XN-8-Gln. 8 
In conclusion, the present study has demonstrated that the novel hybrid peptide Ac-9 
NT/XN-8-Gln is biologically active and can substantially augment exendin-4 benefits in HFF 10 
mice, especially with regards to glucose handling, insulin action and lipid metabolism. 11 
Although further studies are required to uncover the underlying molecular mechanisms, it is 12 
evident that co-activation of GLP-1, neurotensin and xenin pathways represents an antidiabetic 13 
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Table 1. Amino acid sequence, MALDI-TOF MS analysis and enzymatic stability of xenin-8-Gln, acetyl-neurotensin(8-13) and Ac-NT/XN-
8-Gln. 
 
Peptide stability was assessed following 2, 4 and 8 h incubation in murine plasma at 37°C. Degradation products were separated using HPLC, 




Percentage intact peptide remaining (%) 
2 h 4 h 8 h 
Xenin-8-Gln H-HIS-PRO-GLN-GLN-PRO-TRP-ILE-LEU-OH 100 98.3 94.1 
Acetyl-
neurotensin(8-13)  Ac-ARG-ARG-PRO-TYR-ILE-LEU-OH 98.2 94.4 89.6 
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Figure 1. Acute effects of acetyl-neurotensin(8-13), xenin-8-Gln, Ac-NT/XN-8-Gln alone and 
in combination with GIP or GLP-1, on insulin release from BRIN-BD11 cells and isolated 
mouse islets 
BRIN-BD11 cells were incubated (20 min) with a range of concentrations (10-12 to 10-6 M) of 
acetyl-neurotensin(8-13), xenin-8-Gln or Ac-NT/XN-8-Gln alone (A,B) or in combination with 
GIP (C) or GLP-1 (D) in the presence of (A,C,D) 5.6 or (B) 16.7 mM glucose. (E) Murine islets 
were incubated (60 min) with Ac-NT/XN-8-Gln (10-8 and 10-6 M) in the presence 16.7 mM 
glucose. (A-E). Insulin release was measured using radioimmunoassay. Values represent means 
± SEM (n=8 for A-D and n=5 for E). *p<0.05, **p<0.01 and ***p<0.001 compared to respective 
glucose controls. ∆p<0.05, ∆∆p<0.01 and ∆∆∆p<0.001 compared to respective 10-7 M GIP or GLP-
1 control.  
 
Figure 2. Effect of acetyl-neurotensin(8-13), xenin-8-Gln and Ac-NT/XN-8-Gln on beta-cell 
proliferation and protection against apoptosis.  
BRIN-BD11 cells were incubated overnight (18 hours) with exendin-4, acetyl-neurotensin(8-13), 
xenin-8-Gln or Ac-NT/XN-8-Gln (each at 10-8 and 10-6 M). (A) Proliferation was measured using 
Ki-67 immunocytochemistry. (B) Caspase-3/7 activation was detected by luminescence. (A) 
Values represent means ± SEM (n=3-4). **p<0.01 and ***p<0.001 compared to respective media 
control. ∆∆p<0.01 and ∆∆∆p<0.001 compared to respective Ac-NT/XN-8-Gln. (B) Values are mean 
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Figure 3. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or 
in combination, on body weight, food intake, glucose, insulin and HbA1c concentrations in 
HFF mice. 
(A,B,D,F) Parameters were measured for 6 days before and 32 days during (indicated by black 
horizontal line in panels B,D,F) twice-daily treatment with saline, exendin-4, Ac-NT/XN-8-Gln 
or a combination of both (each at 25 nmol/kg) in HFF mice. (C,E) Parameters were assessed on 
day 32. Values represent mean ± SEM (n=6-8). *p<0.05, **p<0.01 and ***p<0.001 compared to 
HFF saline control mice. 
 
Figure 4. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or 
in combination, on glucose tolerance and metabolic response to GIP. 
Test were performed following 32 days twice-daily i.p. administration of saline, exendin-4, Ac-
NT/XN-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) in 10 h fasted HFF 
mice. (A-D) Blood glucose (A) and plasma insulin (C) were measured prior to and after oral 
administration of glucose alone (18 mmol/kg bw). (E-H) Blood glucose (E) and plasma insulin 
(G) were measured prior to and after i.p. administration of glucose (18 mmol/kg bw) in 
combination with GIP (25 nmol/kg bw). (B,D,F,H) Corresponding 0-120 min AUC values are 
also shown. Values represent mean ± SEM (n=6-8). *p<0.05 and **p<0.01 compared to HFF 
saline control mice. +p<0.05 compared to Ac-NT/XN-8-Gln treated HFF mice. ∆p<0.05 compared 
to lean saline control mice. Where appropriate to aid interpretation, lines are used to indicate 
significance between groups on the bar graphs. 
 
Figure 5. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or 
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Test were performed following 32 days twice-daily i.p. administration of saline, exendin-4, Ac-
NT/XN-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) in HFF mice. (A,B) 
Blood glucose was measured prior to and after i.p. administration of insulin (25 U/kg bw), with 
0-60 min AAC values also shown. (C-E) Effects of test peptides on circulating (C) triglycerides, 
(D) total- and (E) LDL-cholesterol concentrations. Values are mean ± SEM (n=6-8). *p<0.05 
**p<0.01 and ***p<0.001 compared to HFF saline control mice. +p<0.05 and ++p<0.01 compared 
to Ac-NT/XN-8-Gln treated HFF mice. Where appropriate to aid interpretation, lines are used to 
indicate significance between groups on the bar graphs. 
 
Figure 6. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or 
in combination, on pancreatic insulin content and islet histology in HFF mice 
Effects of 32 days twice-daily i.p. administration of saline, exendin-4, Ac-NT/XN-8-Gln or a 
combination of both peptides (each at 25 nmol/kg bw) on (A) pancreatic insulin content as well 
as (B) islet, (C) beta-cell and (D) alpha-cell areas in HFF mice. Values represent mean ± SEM 
(n=6-8). +++p<0.001 compared to lean control. *p<0.05, **p<0.01 and ***p<0.001 compared to 
HFF saline control mice. ΔΔp<0.01 and ΔΔΔp<0.001 compared to Ac-NT/XN-8-Gln treated HFF 
mice. Where appropriate to aid interpretation, lines are used to indicate significance between 
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